Searched for
ANTIDEPRESSANT SALES
Escitalopram, Clonazepam become household names as mood elevators, antidepressants conquer new frontiersThe sale of antidepressants and mood elevators in India surged from Rs 1,540 crore in 2020 to Rs 2,536 crore by Nov 2024. Popular drugs lik...- India ranks 126th in World Happiness Index 2023 amidst rising mental health concernsIndia ranks 126th out of 146 countries in the World Happiness Index, indicating low levels of happiness. The decline has been attributed to...
- Lupin gets tentative nod from USFDA to market generic Brexpiprazole tabletsThe company has received tentative approval from the United States Food and Drug Administration (USFDA) to market generic Brexpiprazole tab...
- Drug sales show the times are bad for mental healthData sourced from market research firm AIOCD-AWACS show a 13% year-on-year jump in sales of CNS (central nervous system) drugs for the June...
- Lupin launches generic antidepressant tablets in USThe company has launched its Fluoxetine tablets USP in the strength of 60mg after having received an approval from the United States Food a...
- Lupin launches generic drug to treat depression in USLupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations,...
- Lundbeck to seek legal recourse after health ministry bans Deanxit againThe government had first banned the drug in June last year after noting that it was not approved for marketing in several developed markets.
- Sun Pharmaceutical Industries recalls Venlafaxine Hydrochloride after failing a dissolution testThe recall was made by Sun Pharma’s US subsidiary Caraco Pharmaceutical Laboratories for drugs manufactured in the company’s Indian facilit...
- Zydus Cadila gets USFDA nod for anti-depressant drugDrug major Zydus Cadila has received approval from the US health regulator to market Bupropion Hydrochloride extended-release tablets, an a...
- Zydus Cadila gets USFDA nod to sell drugs in the US market"Zydus Cadila received the final approval from the USFDA to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity,"
- Ranbaxy Deal – A positive trigger for Alembic Pharma's stockThere are 5 buy recommendations for the company's stock with a target price of Rs 99. The company's stock has hit the target price on Frida...
- Cipla to meet revised targetsFor Cipla which has seen a recovery in growth in the past two quarters, the performance in the quarter to June was one of its best.
- Cipla posts 52% profit growth in June quarterThis growth in the domestic market helped Cipla clock a 52% increase in net profit to Rs 401 crore from Rs 253 crore
- Lupin gets US FDA nod for anti-depressantPharma major Lupin on Tuesday said it has received final approval from the US health regulator for its anti-depression drug Imipramine Pamo...
- Lupin settles case with WyethLupin has struck an out-of-court settlement with Wyeth relating to the foreign company’s antidepressant ‘Effexor XR’ capsules.
- Lilly 1Q profit rises on higher sales, flat costsDrugmaker Eli Lilly & Co. said Monday its first-quarter profit rose 24 per cent on a boost in sales of the antidepressant Cymbalta and the ...
- Mumbai tops in anti-depressant drugs saleMumbai has recorded a 30% growth in the sale of anti-depressant medicines in the 12-month period ended August. Survive credit crisis | Will...
- Cadila gets FDA approval to market four drugs in USPharma major Zydus Cadila on Thursday said it has received approval from the US FDA to market four products, including anti-depressant Esci...
- Cadila bags USFDA nod for 3 productsPharmaceutical firm, Cadila Healthcare today said USFDA has given its nod it for the company's three products, taking the group's total num...
- Lupin gets US nod for SertralineDomestic drug maker Lupin on Tuesday said USFDA has granted tentative approval for the company's Abbreviated New Drug Application (ANDA) fo...
Load More
